0.75
-0.0669(-8.21%)
Currency In USD
Address
737 North Fifth Street
Mountain View, VA 23219
United States of America
Phone
909 488 0844
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
June 30, 2020
| Name | Title | Pay | Year Born |
| Amro A. Albanna | Co-Founder, Chairman, CEO & President | 500,000 | 1970 |
| Shahrokh Shabahang | Co-Founder, Chief Innovation Officer, Secretary & Director | 325,000 | 1963 |
| Corinne D. Pankovcin | Chief Mergers & Acquisitions Officer | 385,008 | 1966 |
| Thomas J. Farley | Chief Financial Officer | 464,616 | 1973 |
| Dolly Tyan | Senior Vice President of Clinical Development Transplantation | 0 | N/A |
| Ge Chen | Senior Vice President of Preclinical Research & Discovery | 0 | N/A |
| Jennifer Lee | Director of Human Resources | 0 | N/A |
| Rowena Albanna | Chief Operating Officer | 0 | 1966 |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.